Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q3 EPS of ($0.20), $0.03 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $67.05 million versus the consensus estimate of $64.55 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.